Multi-gene NGS assay for targeted therapy selection
- Tissue-based (FFPE) sample: Actionable mutations for 12 cancers types. Drugs recommendation & drugs resistance mechanism based on FDA guidelines.
- ctDNA blood sample: Apply only for Lung (NSCLC), Breast, Colorectal, Ovarian & Gastric cancers. (Contact us for technical specification variations) (*)
(*) (Tran, Le Son, et al. 'Ultra-deep massively parallel sequencing with unique molecular identifier tagging achieves comparable performance to droplet digital PCR for detection and quantification of circulating tumor DNA from lung cancer patients.' PLoS One 14.12 (2019): e0226193.)
Clinically validated test performance
Tissue sample (FFPE)
VAF >=
0%LoD
0.0%
Sensitivity
>
0%Specificity
0%
Accuracy
Blood sample
VAF >=
0.0%LoD
0.0%
Sensitivity
>
0%Specificity
0.0%
Accuracy
Source: Tran, Le Son, et al. 'Ultra-deep massively parallel sequencing with unique molecular identifier tagging achieves comparable performance to droplet digital PCR for detection and quantification of circulating tumor DNA from lung cancer patients.' PLoS One 14.12 (2019): e0226193.
Scope of the test
Testing candidates
Lung
cancer patient
Formalin fixed paraffin embedded (FFPE) tissue/blood/pleural fluid
Breast/Ovarian
cancer patient
Formalin fixed paraffin embedded (FFPE) tissue/blood
Colorectal/Stomach
cancer patient
Formalin fixed paraffin embedded (FFPE) tissue/blood
GIST
cancer patient
Formalin fixed paraffin embedded (FFPE) tissue
